Friday, November 13, 2026

Corn Futures Bullish Momentum With A 4% Jump In The Last 5 Sessions

Corn Futures Bullish Momentum With A 4% Jump In The Last 5 Sessions

(VIANEWS) - Corn (ZC) has been up by 4.16% for the last 5 sessions. At 14:54 EST on Wednesday, 14 June, Corn (ZC) is $550.25.

Volume

Today's last reported volume for Corn is 138772, 16.24% above its average volume of 119376.5.

Volatility

Corn's last week, last month's, and last quarter's current intraday variation average was a negative 7.73%, a negative 3.83%, and a positive 4.49%, respectively.

Corn's highest amplitude of average volatility was 8.13% (last week), 4.88% (last month), and 4.49% (last quarter), respectively.

News about

  • Crude oil forecast: continues to see a lot of noisy behavior - 12 June 2023. According to DailyForex on Monday, 12 June, "In contrast, the Brent Crude Oil market exhibited a relatively quiet trading session on Friday. ", "Overall, the WTI Crude Oil market is grappling with uncertainties surrounding demand and supply, while the Brent market faces resistance from the 50-Day EMA. "
  • According to FXStreet on Tuesday, 13 June, "On the flip side, any attempted recovery might now confront some resistance near the $68.00 round figure, above which a bout of a short-covering has the potential to lift Crude Oil prices to the $68.50-$68.55 resistance zone. ", "This continues to weigh on Crude Oil prices ahead of the crucial US CPI report, which might influence the Fed's policy outlook and drive the US Dollar (USD) price dynamics."

More news about Corn (ZC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com